The US FDA on Wednesday ​approved Sanofi's oral drug venglustat, the first treatment approved for ‌a type ​of rare genetic condition affecting the brain and nervous system.The drug, branded as Infilbray, is approved to treat type 3 Gaucher disease, the neurological variant of the disorder that causes certain fatty substances to accumulate in organs and tissues.Under new CEO ⁠Belén Garijo, Sanofi is seeking to reduce its reliance on the…